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1008-120 Overexpression of 5-Lipoxygenase Induces Pulmonary 
Hypertension in Bone Morphongenetic Protein 
Receptor-?-Deficient Mice 
Yanli Sonq, John Jones, Jennifer Walker, Wellington Cardoso, Hldeyuki Beppu, En Li, 
Ying-Yi Zhang, Joseph Loscalzo, Boston University Medical Center, Boston, MA. 
Massachusetts General Hospital, Boston, MA 
Background: Mutations in bone morphogenetic protein receptor-2 (BMPRP) have been 
associated with some familial forms of primary pulmonary hypertension (PPH). Because 
only approximately 20% of individuals with these mutations clinically manifest PPH, envi- 
ronmental (epigenetic) or other disease-modifying genes are likely to be important in dis- 
ease pathogen&s. One such candidate disease-modifying gene could be 5- 
lipoxygenase (5LO), whose expression is increased in patients with PPH. 
Methods: In this study, we examined the consequences of 5L0 overexpression in the 
lungs of mce heterozygous for the mutated BMPRP gene (+/-). 
Results: BMPRZ (+/-) mice had normal pulmonary artery systolic pressures (10 * 2 
mmHg, n=5), compared to wild type mice (11 + 2 mmlig. n=7). Delivery of a replication- 
deficient adenovirus expressing 5L0 to the lungs of BMPRP (+/-) mice led to an increase 
in pulmonary artery systolic pressure (24 * 1 mmHg, n=7) by day 12. at which time wild 
type mice treated with the same adenoviral vector containing 5L0 maintained normal 
pressures (13 f 4 mmHg, n=7). These data show that 5.LO modifies the susceptibility of 
BMPRP (+/-) mice to the development of PPH. Prior data usmg cultured endothelial and 
vascular smooth muscle cells showed that 5L0 expression and BMPRP haploinsuff- 
ciency both can promote vascular cell proliferation, and that 5L0 can induce endothelial 
and vascular dysfunction. 
Conclusion: Our data in mice together wth these earlier observations in cultured cells 
suggest a potential mechanism by which these molecular mediators suppolt the develop- 
ment of PPH by promoting vascular dysfunction and cell growth. 
1008-121 Glucocorticoids Suppress Pulmonary Hypertension 
After Cardiopulmonary Bypass by Reducing Endothelin 
and Neutrophil Adhesion Molecules in Neonatal Lungs 
Jefferv M. Pearl, Steven M. Schwartz, David P. Nelson, Connie J. Wagner, John P. 
Lombardi, Jodie Y. Duffy, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 
Background: Glucocorticoids during cardiopulmonary bypass (CPB) benefit pediatric 
patients undergoing repair of congenltal heart defects. Glucocorticoid administration dur- 
Ing CPB has become routine therapy, but underlying mechanisms have not been fully 
examined. The hypothesis was that glucocorticoids could improve cardiopulmonary 
recovery after CPB and deep hypothermic circulatory arrest (DHCA) in part by reducing 
neutrophil activity in the lungs. 
Methods: Piglets (4-6 kg) were cooled on CPB with 2 hr of DHCA, then rewarmed and 
maintained for 2 hr. Methylprednisolone was administered both 6 hr before CPB (30 mg/ 
kg, IM) and in CPB pump prime (30 mglkg). Controls received no steroid treatment. 
Results: Pulmonary vascular reststance (PVR) in controls increased from a basellne of 
152 +/- 40 to 364 +/- 29 (dynes x s)/cm5 at 2 hr of recovery (Pc.01 vs baseline). Animals 
receiving glucocorticoids had no increase in PVR at 2 hr of recovery (155 +I- 54 (dynes x 
s)/cm5). Plasma endothelin-1 in controls increased from 1.3 +/- .2 pg/mL at basallne to 
14.2 +/- 2.9 pg/mL at 2 hr of recovery (Pc.01 vs baseline), while glucocorticoid-treated 
animals had endothelin-1 levels of 4.7 +/- .6 pg/mL (Pc.05 vs controls). Intercellular 
adhesion molecule (ICAM)-l protein and mRNA in lung tissue was lower in animals 
receiving glucocorticoids (Pc.05). Although total NF-KB, a transcriptional regulator of 
ICAM- expression, in lung tissue was not different between treatments, levels of the NF- 
KB Inhibitor, IKB, were higher in animals receiving glucocorticoids (Pc.05). Myeloperoxi- 
dase acwty, an Indicator of neutrophil activation, was elevated at 2 hr of recovery in con- 
trol lungs compared with glucocotiicoid animals (Pc.05). 
Conclusions: Glucocorticoids prevented the rise in PVR after CPB and DHCA in neo- 
nates. Improved cardiopulmonary recovery with glucocorticoid treatment correlated with 
lower plasma ehdothelin-1, as well as, reduced pulmonary ICAM- levels and myeloper- 
oxidase activity. Reduction of neutrophil adhesion and activation by glucocorticoids con- 
tributes to alleviation of pulmonary hypertension after CPB and DHCA. 
1008-l 22 Effects of Overexpression and Inhibition of 5- 
Lipoxygenase on the Development of Pulmonary 
Hypertension in a Rat Model 
John Jones Jennifer Walker, Yanli Song, Wellington Cardoso. Rubin Tuder, Antoinette -I 
Hayes. Norbert Weiss, Joseph Loscalzo, Ying-Yi Zhang, Boston University Medical 
Center, Boston, MA, Johns Hopkins Medical School, Baltimore, MD 
Background: Increased expression of 5.lipoxygenase (5.LO) has been demonstrated in 
patients with primary pulmonary hypertension. In this study. we examined the effect of 
increased expression or inhibition of 5.LO on the development of pulmonary hyperten- 
sion (PH) I” a rat model. 
Methods: Increased expression of 5.LO was achieved by adenovirus-mediated gene 
transfer, and inhibition of &LO was achieved by intraperitoneal injection of MK666 (an 
Inhibitor of 5.LO actwating protein) or by oral gavage with Zileuton (a specific 5.LO inhib- 
itor). 
Results: Overexpression of 5.LO did not itself lead to the development of PH in normal 
rats; however, overexpression of 5-LO markedly accelerated the development of PH in 
rats treated with monocrotaline (MCT), a compound that causes pulmonary artery endot- 
helial dysfunction and damage. Also, both MK666 and Zileuton prevented the develop- 
ment of PH in rats treated with either MCT or MCT + 5-LO. On day 10. rats treated with 
MCT, MCT + 5.LO, MCT + 5-LO + MK686. and MCT + 5.LO + Zileuton had pulmonary 
pressures of 15 * 4, 25 + 4, 15 * 2, and 16 * 4 mmHg, respectively (peO.05). On day 35, 
rats treated with MCT. MCT + MK686, or MCT + Zileuton had pulmonary artery systolic 
pressures of 47 * 6, 16 f 6, and 16 * 5 mmHg, respectively; pcO.05. These data show 
that 5-LO and/or its inflammatory mediators alone do not cause PH, but contributes to 
the development of PH in the setting of endothelial dysfunction or injury. 
Conclwon: These data suggest that 5-LO may represent a disease-modifying gene that 
regulates the susceptibility of an indwidual to the PH phenotype. 
1008-l 23 Role of Arginase in the Pulmonary Vascular Response 
to Chronic Hypoxia in the Mouse: Augmentation of 
Responses by In Vivo Gene Transfer 
Trinity J. Bivalacqua. Hunter C. Champion, The Johns Hopkins Hospital, Baltimore, MD, 
Tulane University, New Orleans, LA 
Arginase is a binuclear manganese metalloenzyme that catalyzes the hydrolysis of of L- 
arginine to form L-ornithine and urea thus regulating NOS activity by depleting the pool of 
L-arginine in the vascular endothelium. This enzyme has been suggested to play a role in 
reducing NO-mediated resporises. However, the role of arginase in regulating NOS activ- 
ity in the lung has not been addressed. The present study was designed to compare argi- 
nase expression, activity, and functional role in the pulmonary vascular bed of the 
mouse. Arginase mRNA, protein, and activity were significantly greater in mice exposed 
to 30 days of chronic hypoxia when compared to control mice. In contrast, while eNOS 
mRNA and protein were elevated in hypoxlc mice, eNOS activity was lower when com- 
pared to norm&c mwa. However, when assessed in the presence of ABH (a potent, 
selective inhibitor of arginase), NOS activity returned to levels similar to those observed 
in normoxic mice. In viva studies I” the pulmonary vascular bed of the intact-chest mouse 
revealed that chronic administration of ABH to hypoxic mice reduced the elevated pulmo- 
nary arterial pressure (PAP), pulmonary vascular resistance (PVR), and increase in RV 
free wall weight (RVFWW) associated with hypoxia. In contrast, in viva gene transfer of 
arginase, wng an adenoviral vector, resulted in higher PAP, PVR and increased 
RVFWW. When taken collectively, these data suggest that increased argmase expres- 
slon plays a role in the exprasslon of pulmonary hypertension in chronic hypoxia. We 
hypothesize that arginase may function by depleting endothelial levels of L-arginine and 
thus reduce the NOS actvity thus the augmenting the hypoxic response in the mouse. 
1008-l 24 Effects of Sildenafil on Growth and Viability of Cultured 
Human Pulmonary Artery Smooth Muscle Cells 
Alessandra Manes Benedetta Tantini. Nazzareno Gal& Ghazwan Butrow, Mania 
Fattori, Carlo Guamieri. Claudia Marcello Caldarera, Angelo Branzl, Institute of 
Cardiology, University of Bologna, Bologna, Italy 
Backgrounct The rationale for a new treatment for pulmonary arterial hypertension 
(PAH) should be based on the demonstration of both vasodilator and antiproliferative 
activities on pulmonary artery smooth-muscle cells (PASMC). Sildenafil, an orally-active 
inhibitor of cGMP phosphodiesterase type 5. exerts potent pulmonary vasodilator activity 
in PAH patients. We evaluated the effects of sildenafil on growth and viability of cultured 
human PASMC. 
Methods: PASMC were cultured in 0.5% serum for 72 hours. Growth was stimulated by 
100 nglml PDGF. Different concentrations of sildenafil were added to the culture (lo-50- 
100 nM). At baseline, 24, 46 and 72 hours Cell proliferation was measured by MTT 
metabolism and by cell number count and cell viability was evaluated by trypan blue 
exclusion method at baseline, 24, 46 and 72 hours. The experiments were repeated after 
the selective inhibition of protein kinase G (PKG) or A (PKA). Four sets of experiments 
were performed for each combination. 
Results: 50 or 100 nM sildenafil significantly reduced PASMC proliferation as assessed 
by both MTT metabolism and cell number count (Fig 1). PASMC viability was not 
affected by sildenafil. The antiproliferative effect of sildenafil was blupted only in part by 
the selective inhibition of PKG or PKA (27+3 x lo4 vs 44i6 x IO4 or 44-6 x l@ cell num- 
her. p < 0.004 by ANOVA). 
Conclusions: Sildenafil exerts a potent antiproliferatwe effect on PASMC stimulated by 
PDGF. This effect is mediated via both cGMP and CAMP dependent pathways. 
